Sen. Tina Smith Sells Off Shares of Insulet Corporation (NASDAQ:PODD)

Senator Tina Smith (Democratic-Minnesota) recently sold shares of Insulet Corporation (NASDAQ:PODD). In a filing disclosed on May 10th, the Senator disclosed that they had sold between $100,001 and $250,000 in Insulet stock on May 7th.

Senator Tina Smith also recently made the following trade(s):

• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 5/7/2026.
• Sold $100,001 – $250,000 in shares of DexCom (NASDAQ:DXCM) on 4/29/2026.
• Sold $100,001 – $250,000 in shares of Insulet (NASDAQ:PODD) on 4/29/2026.
• Sold $50,001 – $100,000 in shares of 3M (NYSE:MMM) on 3/31/2026.
• Sold $100,001 – $250,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 3/31/2026.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $154.17 on Tuesday. Insulet Corporation has a 1-year low of $148.30 and a 1-year high of $354.88. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. The business has a fifty day moving average price of $207.40 and a 200-day moving average price of $261.40. The company has a market capitalization of $10.68 billion, a PE ratio of 35.85, a PEG ratio of 1.25 and a beta of 1.20.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The company had revenue of $761.70 million for the quarter, compared to analysts’ expectations of $729.89 million. During the same quarter in the previous year, the business posted $1.02 EPS. Insulet’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities analysts expect that Insulet Corporation will post 6.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PODD shares. Truist Financial dropped their target price on shares of Insulet from $315.00 to $250.00 and set a “buy” rating on the stock in a research note on Thursday. TD Cowen downgraded shares of Insulet from a “buy” rating to a “hold” rating and set a $294.00 price target for the company. in a research report on Monday, January 26th. Citigroup lowered their price objective on Insulet from $230.00 to $175.00 in a research report on Thursday, May 7th. Royal Bank Of Canada cut their target price on Insulet from $325.00 to $280.00 and set an “outperform” rating on the stock in a research note on Thursday. Finally, Jefferies Financial Group reduced their target price on Insulet from $400.00 to $360.00 in a report on Thursday, May 7th. Nineteen investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $257.09.

Institutional Trading of Insulet

Large investors have recently made changes to their positions in the stock. Winnow Wealth LLC bought a new position in Insulet in the third quarter valued at about $862,000. Nordea Investment Management AB boosted its position in Insulet by 35.0% in the fourth quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock worth $157,128,000 after purchasing an additional 142,922 shares during the last quarter. Jain Global LLC grew its stake in shares of Insulet by 148.2% during the 3rd quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after purchasing an additional 63,719 shares during the period. Machina Capital S.A.S. purchased a new stake in shares of Insulet during the 3rd quarter valued at about $2,778,000. Finally, ING Groep NV increased its position in shares of Insulet by 88.5% during the 3rd quarter. ING Groep NV now owns 17,300 shares of the medical instruments supplier’s stock valued at $5,341,000 after purchasing an additional 8,123 shares during the last quarter.

Insider Buying and Selling at Insulet

In other Insulet news, Director Michael R. Minogue acquired 2,030 shares of the company’s stock in a transaction that occurred on Wednesday, February 25th. The shares were bought at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the acquisition, the director owned 17,483 shares in the company, valued at $4,304,839.09. This represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.36% of the stock is owned by company insiders.

About Senator Smith

Tina Smith (Democratic Party) is a member of the U.S. Senate from Minnesota. She assumed office on January 3, 2018. Her current term ends on January 3, 2027. Smith (Democratic Party) ran for re-election to the U.S. Senate to represent Minnesota. She won in the general election on November 3, 2020. Smith succeeded former Senator Al Franken (D). She assumed office on January 3, 2018. Smith won a full term in the special general election for the position on November 6, 2018. She defeated Karin Housley (R), Sarah Wellington (Legal Marijuana Now Party), and Jerry Trooien (Unaffiliated) to win the seat. She advanced to the general election after defeating five challengers in the special Democratic primary election on August 14, 2018. Smith previously served as the 48th lieutenant governor of Minnesota. She was elected to the position on a joint ticket with incumbent Governor Mark Dayton on November 4, 2014, and was sworn into office on January 5, 2015.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.